Abstract
401MO OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have